Executive Profile:/ J&J Benelux Director Heads to Iberia
Brazilian national Maria Fernanda Prado, who began her career in pharma more than 20 years ago, has been at Janssen/Johnson & Johnson for more than half of that time. She…
Brazilian national Maria Fernanda Prado, who began her career in pharma more than 20 years ago, has been at Janssen/Johnson & Johnson for more than half of that time. She…
2023 was a breakthrough year for cell and gene therapies. The field saw a record number of FDA approvals, as other promising therapies in a broad range of therapeutic areas…
The latest stories from Mexican pharma and healthcare, including Sanfer’s purchase of Colombia-based manufacturer Vitalis; Organon Mexico’s new business; the FDA’s warning to Glicerinas Industriales, and a look at the issues,…
Having been quietly working away on its mRNA platform for years, Moderna stepped into the limelight during the COVID-19 pandemic and became a commercial-stage outfit almost overnight with its vaccine.…
While the Swiss biotech sector is inevitably facing many of the same funding challenges as the global industry and is still struggling to make a meaningful comeback from its 2022…
Nigeria has become the first country to roll out a new meningitis vaccine. The product, a shot able to protect against the five causes of meningococcal meningitis, was developed by…
Since it was established in 1988, PhIRDA, an organization that groups together China’s pharma innovators, research institutions and investors has played an active role in the evolution of China’s biopharma…
A roundup of some of the biggest stories from Italian pharma and healthcare, including Italfarmaco’s FDA approval for its DMD treatment; Alfasigma’s acquisition of Galapagos’s Jyseleca, the antibiotics deal between…
Johnson & Johnson has been building its medtech arm and creating a differentiated pipeline through strategic M&A, an approach that generated USD 30.4 billion in medical device sales last year,…
A roundup of some of the biggest stories coming out of the UK pharma industry, including AstraZeneca’s bid for cancer specialist Fusion Pharmaceuticals; the shutdown of Sanofi’s R&D site in…
Sovereign wealth funds (SWFs) in the Gulf Cooperation Council (GCC) countries are increasingly investing in healthcare and the life sciences to reinforce their local industries and pursue the region’s economic…
Thanks to what AstraZeneca country president Rick Suarez called a “thriving life-science eco-system and highly-skilled talent pool,” along with Spain’s leading position in clinical trials, the British Big Pharma is…
See our Cookie Privacy Policy Here
